CC
SABS icon

Commodore Capital’s SAB Biotherapeutics SABS Stock Holding History

Commodore Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Sell
2,870,000
-1,531,500
-35% -$5.7M 0.67% 26
2026
Q1 		$16.9M Hold
4,401,500
– – 0.98% 27
2025
Q4 		$16.5M Hold
4,401,500
– – 1.1% 26
2025
Q3 		$8.85M Buy
+4,401,500
New +$9.95M 0.43% 32
2024
Q2 		– Sell
-183,174
Closed -$832K – 41
2024
Q1 		$832K Sell
183,174
-1
-0% -$6 0.06% 38
2023
Q4 		$1.26M Buy
+183,175
New +$1.54M 0.11% 31

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Commodore Capital's SABS Position: Q2 2026 in Review

Commodore Capital reduced its SAB Biotherapeutics (SABS) stake by 35% in Q2 2026, selling an estimated $5.7M and leaving 2,870,000 shares worth $11.2M. The position accounts for 0.67% of the portfolio, ranked #26.

Commodore Capital first reported a position in SABS in Q4 2023 and has held it in 6 quarters since. The position peaked at $16.9M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Commodore Capital held 2,870,000 shares of SAB Biotherapeutics worth $11.2M as of Q2 2026.
  • Commodore Capital sold 1,531,500 SAB Biotherapeutics shares in Q2 2026, an estimated $5.7M.
  • SAB Biotherapeutics made up 0.67% of Commodore Capital's portfolio in Q2 2026, its #26 holding.
  • Commodore Capital first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 6 quarters since.
  • Commodore Capital's SAB Biotherapeutics position peaked at $16.9M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.